SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 or 15d-16 OF
THE SECURITIES EXCHANGE ACT OF 1934
Report on Form 6-K dated June 26, 2002
Novartis AG
(Name of Registrant)
Lichtstrasse 35
4056 Basel
Switzerland
(Address of Principal Executive Offices)
Indicate by check mark whether the registrant files or will file
annual reports under cover of Form 20-F or Form 40-F.
Form 20-F X Form 40-F
-- --
Indicate by check mark whether the registrant by furnishing the information
contained in this form is also thereby furnishing the information to the
Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes No X
-- --
Enclosures:
1. Invitation for Telephone Conference, First Half 2002 Sales & Results; and
2. Pre-Results Announcement, Quarterly Breakdown 2001.
NOVARTIS LOGO Investor Relations Novartis International AG
CH-4002 Basel
Switzerland
Karen J Huebscher, PH.D.
Tel +41 61 324 8433
Nafida Bendali
Tel +41 61 324 3514
Sabine Moravi, MBA
Tel + 41 61 324 8989
Fax + 41 61 324 8844
Silke Zentner
Tel + 41 61 324 8612
Francisco Bouzas
Tel + 41 61 324 2462
Fax + 41 61 324 8844
Internet Address:
http://www.novartis.com
- INVITATION FOR TELEPHONE CONFERENCE -
First Half 2002 Sales & Results
Dear Investor
We are pleased to invite you to our First Half Sales & Results 2002 conference
call. Please below the following dial-in numbers:
Date: Monday, July 22, 2002
Time: Advisable: dial-in 10 minutes before
06.00 p.m. Switzerland
05.00 p.m. UK
12.00 p.m. New York
Phone numbers: +41 91 610 4111 or Free-phone +800 2467 8700 Europe and ROW
+1 800 860 2442 US
You may access the conference call as a live audio webcast on the Internet:
http://www.novartis.com/investors (under Upcoming Event). This information will
be available for tests and for the submission of questions in advance from July
15, 2002 on.
Additional information will be available on Monday, July 22, on the Internet
http://www.novartis.com/investors/sales_results_releases.shtml
Playback for 48 hours
Date: Monday, July 22, 2002
Time: 07.00 p.m. Switzerland
06.00 p.m. UK
01.00 p.m. New York
Phone numbers: +41 91 612 43 30 Europe and ROW
+1 877 344 7529 US
Code: 335 (followed by the # sign)
NOVARTIS LOGO
Pre-Results Announcement
Quarterly Breakdown 2001
Investor Relations, June 2002
Comments
--------------------------------------------------------------------------------
On the following slides you will find for 2001
o Sector sales and operating income figures updated for the split of
Consumer Health into OTC, Medical Nutrition and Infant & Baby
o Sector sales figures showing a regional breakdown into US and RoW
o Breakdown of quarterly operating margins
NOVARTIS LOGO
Quarterly Breakdown of Sales by Sector 2001
--------------------------------------------------------------------------------
First Quarter Q1 Second Quarter Half Year
US RoW Total US RoW Total
CHF m CHF m CHF m CHF m CHF m CHF m
----- ----- ----- ----- ----- ---------
Group 2,876 4,348 7,224 3,341 4,702 15,267
Pharmaceuticals 1,793 2,745 4,538 2,174 2,977 9,689
Generics 156 372 528 176 417 1,121
OTC 175 426 601 181 432 1,214
Animal Health 75 165 240 74 176 490
Medical Nutrition & HFF 97 276 373 111 293 777
Infant & Baby 401 120 521 427 147 1,095
CIBA Vision 179 244 423 198 260 881
NOVARTIS LOGO
Quarterly Breakdown of Sales by Sector 2001
--------------------------------------------------------------------------------
Third Quarter Q3 Fourth Quarter Full Year
US RoW Total US RoW Total
CHF m CHF m CHF m CHF m CHF m CHF m
----- ----- ----- ----- ----- ---------
Group 3,665 4,452 8,117 3,604 4,655 31,643
Pharmaceuticals 2,395 2,812 5,207 2,275 3,010 20,181
Generics 228 408 636 229 447 2,433
OTC 230 422 652 246 426 2,538
Animal Health 78 147 225 103 144 962
Medical Nutrition & HFF 109 256 365 129 244 1,515
Infant & Baby 412 135 547 453 132 2,227
CIBA Vision 214 271 485 169 252 1,787
NOVARTIS LOGO
Sales Adjustments1 For 2001
--------------------------------------------------------------------------------
Q1 Q2 Half Year Q3 Q4 Full Year
CHF m CHF m CHF m CHF m CHF m
----- ----- --------- ----- ----- ---------
Group -96 -101 -197 -103 -95 -395
OTC -30 -29 -59 -29 -41 -129
Infant & Baby -55 -55 -110 -66 -40 -216
Medical Nutrition & HFF -11 -17 -28 -8 -14 -50
1 adjustments for changes in accounting policy on sales incentives and
discounts to retailers
NOVARTIS LOGO
Quarterly Breakdown of Operating Income by Sector 2001
--------------------------------------------------------------------------------
Q1 Q2 Half Year Q3 Q4 Full Year
CHF m CHF m CHF m CHF m CHF m CHF m
----- ----- --------- ----- ----- ---------
Group 1,545 1,935 3,480 1,873 1,924 7,277
Pharmaceuticals 1,244 1,451 2,695 1,436 1,546 5,677
Generics 65 76 141 68 72 281
OTC 58 92 150 128 174 452
Animal Health 44 22 66 30 42 138
Medical Nutrition & HFF 18 24 42 17 21 80
Infant & Baby 90 103 193 94 101 388
CIBA Vision 6 81 87 69 18 174
Corporate income, net 20 86 106 31 -50 87
NOVARTIS LOGO
Quarterly Breakdown of Operating Margins by Sector 2001
--------------------------------------------------------------------------------
Q1 Q2 Half Year Q3 Q4 Full Year
in % in % in % in % in % in %
---- ---- --------- ---- ---- ---------
Group 21.4 24.1 22.8 23.1 23.3 23.0
Pharmaceuticals 27.4 28.2 27.8 27.6 29.3 28.1
Generics 12.3 12.8 12.6 10.7 10.7 11.5
OTC 9.7 15.0 12.4 19.6 25.9 17.8
Animal Health 18.3 8.8 13.5 13.3 17.0 14.3
Medical Nutrition & HFF 4.8 5.9 5.4 4.7 5.6 5.3
Infant & Baby 17.3 17.9 17.6 17.2 17.3 17.4
CIBA Vision 1.4 17.7 9.9 14.2 4.3 9.7
NOVARTIS LOGO
2001 Quarterly Consolidated Income Statement
Quarterly Breakdown of Operating Margins by Sector 2001
--------------------------------------------------------------------------------
Q1 Q2 1H2001 Q3 Q4 FY2001
CHF CHF CHF CHF CHF CHF
millions millions millions millions millions millions
-------- -------- -------- -------- -------- --------
Total sales 7,224 8,043 15,267 8,117 8,259 31,643
Cost of goods sold -1,874 -1,930 -3,804 -2,000 -2,082 -7,886
Gross profit 5,350 6,113 11,463 6,117 6,177 23,757
Marketing & Distribution -2,499 -2,766 -5,265 -2,689 -2,749 -10,703
Research & Development -929 -1,081 -2,010 -1,057 -1,122 -4,189
General & Administration -377 -331 -708 -498 -382 -1,588
Operating income 1,545 1,935 3,480 1,873 1,924 7,277
Income from associated companies 31 46 77 23 39 139
Financial income, net 217 735 952 197 -82 1,067
Income before taxes and minority interests 1,793 2,716 4,509 2,093 1,881 8,483
Taxes -305 -463 -768 -399 -273 -1,440
Minority interests -3 -9 -12 -11 4 -19
Net income 1,485 2,244 3,729 1,683 1,612 7,024
NOVARTIS LOGO
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.
Novartis AG
Date: June 26, 2002 By: /s/ MALCOLM B. CHEETHAM
--------------------------------
Name: Malcolm B. Cheetham
Title: Head Group Financer
Group Fin. Reporting and Accounting